Humira buyers appeal AbbVie ruling to Seventh Circuit

Buyers of AbbVie’s arthritis treatment Humira (adalimumab) have appealed against an Illinois judge’s decision to dismiss their class action antitrust suit to the US Court of Appeals for the Seventh Circuit.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

ITC to investigate Alvotech’s Humira biosimilar

27 January 2022 The US International Trade Commission will investigate whether drug manufacturers used trade secrets to develop a biosimilar of AbbVie’s Humira.

Americas

Judge refuses to block pay-for-delay law pending appeal

13 January 2020 A judge has refused to temporarily block California’s ban on pay-for-delay deals while a group of generics manufacturers appeal against the judge’s earlier decision.

Americas

Abbvie faces multiple Humira antitrust suits

4 April 2019 AbbVie is now facing six antitrust class-action lawsuits which claim that the company illegally stopped competition for its arthritis treatment Humira.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Humira buyers appeal AbbVie ruling to Seventh Circuit

More on this story

Editor's picks

Editor's picks

More features